Free Trial
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free VOR Stock Alerts

Vor Biopharma (VOR) Financials

Vor Biopharma logo
$15.52 +0.81 (+5.51%)
Closing price 04:00 PM Eastern
Extended Trading
$15.38 -0.14 (-0.87%)
As of 05:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Vor Biopharma

Annual Income Statements for Vor Biopharma

This table shows Vor Biopharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -49 -70 -92 -118 -117 -696
Consolidated Net Income / (Loss)		 -43 -69 -92 -118 -117 -696
Net Income / (Loss) Continuing Operations		 -43 -69 -92 -118 -117 -696
Total Pre-Tax Income 		-43 -69 -92 -118 -117 -696
Total Operating Income		 -43 -69 -93 -126 -121 -372
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 43 69 93 126 121 372
Selling, General & Admin Expense		 12 21 29 32 28 50
Research & Development Expense		 32 48 65 94 93 322
Total Other Income / (Expense), net		 0.03 0.12 1.32 8.17 4.27 -324
Interest & Investment Income		 0.03 0.12 1.32 8.17 4.27 5.87
Other Income / (Expense), net		 - - - - 0.00 -330
Basic Earnings per Share		 ($230.57) ($2.10) ($2.33) ($1.75) ($34.03) ($70.50)
Weighted Average Basic Shares Outstanding		 213.66K 33.43M 39.55M 67.19M 3.44M 9.87M
Diluted Earnings per Share		 ($230.57) ($2.10) ($2.33) ($1.75) ($34.03) ($70.50)
Weighted Average Diluted Shares Outstanding		 213.66K 33.43M 39.55M 67.19M 3.44M 9.87M
Weighted Average Basic & Diluted Shares Outstanding		 213.66K 33.43M 66.37M 68.17M 124.85M 48.85M

Quarterly Income Statements for Vor Biopharma

This table shows Vor Biopharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -30 -33 -26 -31 -28 -28 -31 -32 -1,574 -813 1,723
Consolidated Net Income / (Loss)		 -30 -33 -26 -31 -28 -28 -31 -32 -1,574 -813 1,723
Net Income / (Loss) Continuing Operations		 -30 -33 -26 -31 -28 -28 -31 -32 -1,574 -813 1,723
Total Pre-Tax Income 		-30 -33 -26 -31 -28 -28 -31 -32 -1,574 -813 1,723
Total Operating Income		 -32 -35 -28 -32 -29 -29 -31 -33 -274 -28 -36
Total Operating Expenses		 32 35 28 32 29 29 31 33 274 28 36
Selling, General & Admin Expense		 8.28 7.71 7.23 8.00 7.21 6.70 5.96 6.59 13 14 17
Research & Development Expense		 24 28 21 24 22 22 25 27 261 14 19
Total Other Income / (Expense), net		 2.20 2.13 1.86 1.52 1.20 0.95 0.60 0.81 -1,299 -785 1,759
Interest & Investment Income		 2.20 2.13 1.86 1.52 1.20 0.95 0.60 0.81 0.54 1.73 2.80
Basic Earnings per Share		 ($0.45) ($0.49) ($0.38) ($0.45) ($0.41) ($8.05) ($0.44) ($0.26) ($12.56) ($121.63) $174.52
Weighted Average Basic Shares Outstanding		 67.03M 67.61M 67.19M 68.03M 68.30M 3.42M 68.71M 124.82M 125.27M 6.68M 9.87M
Diluted Earnings per Share		 ($0.45) ($0.49) ($0.38) ($0.45) ($0.41) ($8.05) ($0.44) ($0.26) ($12.56) ($121.63) $174.52
Weighted Average Diluted Shares Outstanding		 67.03M 67.61M 67.19M 68.03M 68.30M 3.42M 68.71M 124.82M 125.27M 6.68M 9.87M
Basic & Diluted Earnings per Share		 - - - - - - - - - - $174.52
Weighted Average Basic & Diluted Shares Outstanding		 67.54M 67.81M 68.17M 68.26M 68.40M 68.67M 124.85M 124.96M 126.68M 10.41M 48.85M

Annual Cash Flow Statements for Vor Biopharma

This table details how cash moves in and out of Vor Biopharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 42 72 -62 -26 51 312
Net Cash From Operating Activities		 -36 -69 -85 -100 -100 -143
Net Cash From Continuing Operating Activities		 -36 -69 -85 -100 -100 -143
Net Income / (Loss) Continuing Operations		 -43 -69 -92 -118 -117 -696
Consolidated Net Income / (Loss)		 -43 -69 -92 -118 -117 -696
Depreciation Expense		 0.61 1.43 2.53 3.49 3.53 2.89
Amortization Expense		 - - -0.01 -4.66 -1.15 -0.07
Non-Cash Adjustments To Reconcile Net Income		 2.12 7.33 3.82 18 15 540
Changes in Operating Assets and Liabilities, net		 4.32 -9.01 0.62 0.65 0.01 10
Net Cash From Investing Activities		 -4.16 -92 -94 71 97 -49
Net Cash From Continuing Investing Activities		 -4.16 -92 -94 71 97 -49
Purchase of Property, Plant & Equipment		 -4.16 -3.89 -8.46 -1.07 -0.23 -0.94
Purchase of Investments		 0.00 -88 -123 -75 -9.91 -54
Sale of Property, Plant & Equipment		 - - - - 0.00 0.80
Sale and/or Maturity of Investments		 - 0.00 38 147 107 5.00
Net Cash From Financing Activities		 83 233 117 2.94 53 504
Net Cash From Continuing Financing Activities		 83 233 117 2.94 53 504
Issuance of Common Equity		 0.00 190 117 4.84 56 505
Other Financing Activities, net		 0.26 - 0.00 -1.90 -2.66 -1.58

Quarterly Cash Flow Statements for Vor Biopharma

This table details how cash moves in and out of Vor Biopharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Change in Cash & Equivalents		 -10 13 -14 14 31 -23 29 -32 141 -32 236
Net Cash From Operating Activities		 -24 -28 -24 -30 -22 -23 -24 -31 -35 -54 -23
Net Cash From Continuing Operating Activities		 -24 -28 -24 -30 -22 -23 -24 -31 -35 -54 -23
Net Income / (Loss) Continuing Operations		 -30 -33 -26 -31 -28 -28 -31 -32 -1,574 -813 1,723
Consolidated Net Income / (Loss)		 -30 -33 -26 -31 -28 -28 -31 -32 -1,574 -813 1,723
Depreciation Expense		 0.87 0.89 0.89 0.94 0.87 0.85 0.87 0.83 2.04 0.00 0.02
Amortization Expense		 -1.25 -1.23 -0.99 -0.80 -0.33 -0.01 -0.01 -0.01 -0.01 -0.01 -0.03
Non-Cash Adjustments To Reconcile Net Income		 5.42 4.36 3.11 4.31 4.04 3.53 2.98 3.24 1,532 754 -1,749
Changes in Operating Assets and Liabilities, net		 0.84 1.27 -0.78 -4.12 1.41 -0.10 2.82 -2.64 4.63 5.06 3.16
Net Cash From Investing Activities		 14 41 10 44 53 -0.03 -0.07 -0.23 0.65 -0.24 -49
Net Cash From Continuing Investing Activities		 14 41 10 44 53 -0.03 -0.07 -0.23 0.65 -0.24 -49
Purchase of Property, Plant & Equipment		 -0.40 -0.47 -0.11 -0.11 -0.01 -0.03 -0.07 -0.23 -0.15 -0.24 -0.31
Purchase of Investments		 -35 0.00 -17 -9.91 -0.00 - - 0.00 - - -54
Sale and/or Maturity of Investments		 49 41 27 54 53 - - 0.00 -0.00 - 5.00
Net Cash From Financing Activities		 0.22 0.18 0.03 0.10 -0.03 0.04 53 -0.61 175 22 308
Net Cash From Continuing Financing Activities		 0.22 0.18 0.03 0.10 -0.03 0.04 53 -0.61 175 22 308
Issuance of Common Equity		 0.78 0.40 0.05 0.28 0.02 0.11 56 0.00 175 22 308
Other Financing Activities, net		 -0.56 -0.22 -0.02 -0.18 -0.05 -0.07 -2.36 -0.06 -0.03 -0.02 -1.47

Annual Balance Sheets for Vor Biopharma

This table presents Vor Biopharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 76 243 299 198 143 464
Total Current Assets		 49 214 237 141 97 458
Cash & Equivalents		 49 120 58 31 82 396
Short-Term Investments		 0.00 88 173 106 9.98 59
Prepaid Expenses		 0.47 4.84 4.37 3.15 4.20 1.15
Other Current Assets		 0.10 2.09 2.34 0.48 0.38 1.75
Plant, Property, & Equipment, net		 4.73 6.85 13 10 6.58 0.53
Total Noncurrent Assets		 22 21 50 47 40 5.49
Other Noncurrent Operating Assets		 22 21 50 47 40 5.49
Total Liabilities & Shareholders' Equity		 76 243 299 198 143 464
Total Liabilities		 28 26 49 47 46 628
Total Current Liabilities		 10 10 13 16 19 25
Accounts Payable		 2.36 1.55 1.77 0.82 1.51 5.13
Accrued Expenses		 6.26 6.34 7.89 11 13 20
Other Current Liabilities		 1.59 2.27 3.46 3.88 4.22 0.28
Total Noncurrent Liabilities		 17 16 36 32 28 603
Other Noncurrent Operating Liabilities		 17 16 36 32 28 603
Total Equity & Noncontrolling Interests		 -59 216 251 151 97 -164
Total Preferred & Common Equity		 -59 216 251 151 97 -164
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -59 216 251 151 97 -164
Common Stock		 2.16 346 474 491 554 989
Retained Earnings		 -61 -130 -222 -340 -457 -1,153
Accumulated Other Comprehensive Income / (Loss)		 - 0.00 -0.77 -0.08 0.02 0.04

Quarterly Balance Sheets for Vor Biopharma

This table presents Vor Biopharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025
Total Assets		 251 223 167 142 116 109 205 176
Total Current Assets		 191 164 112 90 67 65 205 172
Cash & Equivalents		 32 45 45 76 53 50 191 160
Restricted Cash		 - - - - - - 2.41 0.00
Short-Term Investments		 155 115 63 9.86 10 9.99 9.99 10
Prepaid Expenses		 3.95 3.67 3.83 4.05 4.20 4.52 1.50 0.75
Other Current Assets		 0.54 0.67 0.51 0.27 0.29 0.30 0.45 1.28
Plant, Property, & Equipment, net		 11 11 9.17 8.29 7.47 5.99 0.00 0.27
Total Noncurrent Assets		 46 48 46 43 41 38 0.44 3.48
Other Noncurrent Operating Assets		 46 48 46 43 41 38 0.44 3.48
Total Liabilities & Shareholders' Equity		 251 223 167 142 116 109 205 176
Total Liabilities		 47 48 44 44 43 43 1,711 2,402
Total Current Liabilities		 13 15 13 14 14 17 59 19
Accounts Payable		 1.65 1.31 2.33 2.01 1.32 3.73 0.67 0.89
Accrued Expenses		 7.26 10 6.80 7.66 8.85 8.69 58 18
Other Current Liabilities		 3.81 3.81 4.09 4.14 4.18 4.31 0.00 0.25
Total Noncurrent Liabilities		 34 33 31 30 29 27 1,652 2,383
Other Noncurrent Operating Liabilities		 34 33 31 30 29 27 1,652 2,383
Total Equity & Noncontrolling Interests		 204 175 123 98 73 66 -1,506 -2,225
Total Preferred & Common Equity		 204 175 123 98 73 66 -1,506 -2,225
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 204 175 123 98 73 66 -1,506 -2,225
Common Stock		 486 489 494 497 499 556 557 650
Retained Earnings		 -281 -314 -371 -399 -426 -489 -2,063 -2,876
Accumulated Other Comprehensive Income / (Loss)		 -0.44 -0.28 -0.09 -0.07 0.07 0.02 0.01 0.01

Annual Metrics And Ratios for Vor Biopharma

This table displays calculated financial ratios and metrics derived from Vor Biopharma's official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 37,289,504.00 38,666,158.00 67,805,687.00 - 10,410,630.00
DEI Adjusted Shares Outstanding		 0.00 1,864,475.00 1,933,308.00 3,390,284.00 - 10,410,630.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -37.61 -47.64 -34.76 - -66.85
Growth Metrics		 - - - - - -
Profitability Metrics		 - - - - - -
Net Operating Profit after Tax (NOPAT)		 -30 -48 -65 -88 -85 -260
Return On Investment Capital (ROIC_SIMPLE)		 - - - -58.53% -87.76% 158.33%
Earnings before Interest and Taxes (EBIT)		 -43 -69 -93 -126 -121 -702
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -43 -68 -91 -127 -119 -699
Valuation Ratios		 - - - - - -
Leverage & Solvency		 - - - - - -
Liquidity Ratios		 - - - - - -
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -57 -77 -81 -76 364
Efficiency Ratios		 - - - - - -
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -0.27 8.79 20 14 4.74 -620
Increase / (Decrease) in Invested Capital		 0.00 9.06 12 -6.81 -8.81 -624
Book Value per Share		 ($276.45) $5.80 $6.48 $2.22 $1.41 ($15.78)
Tangible Book Value per Share		 ($276.45) $5.80 $6.48 $2.22 $1.41 ($15.78)
Total Capital		 48 216 251 151 97 -164
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -49 -207 -230 -137 -92 -455
Capital Expenditures (CapEx)		 4.16 3.89 8.46 1.07 0.23 0.14
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -9.64 -3.22 -6.41 -12 -14 -22
Debt-free Net Working Capital (DFNWC)		 39 204 224 125 78 433
Net Working Capital (NWC)		 39 204 224 125 78 433
Net Nonoperating Expense (NNE)		 13 21 27 30 32 436
Net Nonoperating Obligations (NNO)		 -49 -207 -230 -137 -92 -455
Total Depreciation and Amortization (D&A)		 0.61 1.43 2.51 -1.17 2.38 2.82
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($2.10) ($2.33) ($1.75) ($1.70) ($70.50)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 37.49M 39.55M 67.19M 68.71M 9.87M
Adjusted Diluted Earnings per Share		 $0.00 ($2.10) ($2.33) ($1.75) ($1.70) ($70.50)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 37.49M 39.55M 67.19M 68.71M 9.87M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($2.10) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 33.43M 66.37M 68.17M 124.85M 48.85M
Normalized Net Operating Profit after Tax (NOPAT)		 -30 -48 -65 -88 -85 -260
Debt Service Ratios		 - - - - - -
Payout Ratios		 - - - - - -

Quarterly Metrics And Ratios for Vor Biopharma

This table displays calculated financial ratios and metrics derived from Vor Biopharma's official financial filings.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
DEI Shares Outstanding		 66,956,800.00 67,538,680.00 67,805,687.00 68,168,771.00 68,259,602.00 68,398,826.00 - 124,851,547.00 124,959,520.00 126,683,111.00 10,410,630.00
DEI Adjusted Shares Outstanding		 3,347,840.00 3,376,934.00 3,390,284.00 3,408,439.00 3,412,980.00 3,419,941.00 - 6,242,577.00 6,247,976.00 6,334,156.00 10,410,630.00
DEI Earnings Per Adjusted Shares Outstanding		 -8.95 -9.83 -7.75 -9.04 -8.16 -8.06 - -5.20 -251.87 -128.30 165.49
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -23 -25 -20 -23 -20 -20 -22 -23 -192 -20 -36
Return On Investment Capital (ROIC_SIMPLE)		 - - -13.06% -18.39% -20.72% -27.36% -22.67% -35.27% 12.75% 0.88% 21.89%
Earnings before Interest and Taxes (EBIT)		 -32 -35 -28 -32 -29 -29 -31 -33 -1,574 -814 -36
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -33 -36 -28 -32 -28 -28 -30 -32 -1,572 -814 -36
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -14 -17 -13 -18 -17 -15 -13 -14 1,529 2,386 588
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 15 15 14 16 12 10 4.74 6.03 -1,709 -2,396 -620
Increase / (Decrease) in Invested Capital		 -8.75 -7.98 -6.81 -4.46 -2.99 -4.54 -8.81 -9.52 -1,721 -2,406 -624
Book Value per Share		 $3.05 $2.59 $2.22 $1.80 $1.44 $21.31 $1.41 $0.53 ($12.05) ($17.57) ($15.78)
Tangible Book Value per Share		 $3.05 $2.59 $2.22 $1.80 $1.44 $21.31 $1.41 $0.53 ($12.05) ($17.57) ($15.78)
Total Capital		 204 175 151 123 98 73 97 66 -1,506 -2,225 -164
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -187 -160 -137 -107 -86 -63 -92 -60 -203 -170 -455
Capital Expenditures (CapEx)		 0.40 0.47 0.11 0.11 0.01 0.03 0.07 0.23 0.15 0.24 0.31
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -8.23 -11 -12 -8.88 -9.48 -9.86 -14 -12 -57 -17 -22
Debt-free Net Working Capital (DFNWC)		 179 149 125 99 76 53 78 48 146 154 433
Net Working Capital (NWC)		 179 149 125 99 76 53 78 48 146 154 433
Net Nonoperating Expense (NNE)		 7.46 8.47 6.57 8.18 7.51 7.60 8.79 9.18 1,382 793 -1,759
Net Nonoperating Obligations (NNO)		 -189 -160 -137 -107 -86 -63 -92 -60 -203 -170 -455
Total Depreciation and Amortization (D&A)		 -0.38 -0.33 -0.09 0.15 0.54 0.84 0.85 0.81 2.03 -0.01 -0.01
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.45) ($0.49) ($0.38) ($0.45) ($0.41) ($8.00) ($0.44) ($0.26) ($12.56) ($121.63) $174.52
Adjusted Weighted Average Basic Shares Outstanding		 67.03M 67.61M 67.19M 68.03M 68.30M 3.42M 68.71M 124.82M 125.27M 6.68M 9.87M
Adjusted Diluted Earnings per Share		 ($0.45) ($0.49) ($0.38) ($0.45) ($0.41) ($8.00) ($0.44) ($0.26) ($12.56) ($121.63) $174.52
Adjusted Weighted Average Diluted Shares Outstanding		 67.03M 67.61M 67.19M 68.03M 68.30M 3.42M 68.71M 124.82M 125.27M 6.68M 9.87M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $174.52
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 67.54M 67.81M 68.17M 68.26M 68.40M 3.43M 124.85M 124.96M 126.68M 10.41M 48.85M
Normalized Net Operating Profit after Tax (NOPAT)		 -23 -25 -20 -23 -20 -20 -22 -23 -192 -20 -25
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Financials Breakdown Chart

Key Financial Trends

Here are the key takeaways from Vor Biopharma's quarterly statements, focusing on the last four years of data provided (2023–2025). Note: 2022 data is not included in the dataset.

  • In Q4 2025, Vor Biopharma reported a very large Net Income figure of about $1.72B, driven by a one-time Total Other Income / (Expense), net of about $1.76B. This non-operating gain boosted earnings but is unlikely to be repeatable in normal operations.
  • Q4 2025 saw a substantial equity raise: Issuance of Common Equity of about $308.1M, contributing to a net financing cash inflow of roughly $307.8M for the quarter.
  • Across 2025, financing activity provided about $0.505B of net cash from financing activities (roughly $0.096M in Q1, $175.1M in Q2, $21.5M in Q3, and $307.8M in Q4), highlighting ongoing access to capital markets.
  • Q4 2025 also produced a positive net change in cash and equivalents of about $236.0M, aided by the financing inflows.
  • Total Revenue remained at zero across the 2025 quarters, consistent with Vor Biopharma's pre-revenue, development-stage business model.
  • Operating cash burn persists: net cash from operating activities was negative in 2025 (e.g., Q4 approximately -$22.9M) and negative in multiple prior quarters, indicating ongoing cash burn before financing activities.
  • Balance sheet risk is evident: in Q3 2025, Total Liabilities were about $2.40B against Total Assets of about $176M, implying negative shareholders’ equity of roughly $2.23B and a high leverage/funding-reliant position.
  • No product revenue is evident in many quarters, with substantial R&D and SG&A expenses driving operating losses in 2025, underscoring the company’s reliance on external financing to fund operations.
  • Occasional sizable non-operating swings (e.g., large fluctuations in Other Income / (Expense)) can drive reported profits in certain periods, making sustainability of earnings questionable and adding investment risk.
05/05/26 06:54 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Vor Biopharma's Financials

When does Vor Biopharma's fiscal year end?

According to the most recent income statement we have on file, Vor Biopharma's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

How has Vor Biopharma's net income changed over the last 5 years?

Vor Biopharma's net income appears to be on an upward trend, with a most recent value of -$695.98 million in 2025, rising from -$43.34 million in 2020. The previous period was -$116.91 million in 2024. Find out what analysts predict for Vor Biopharma in the coming months.

What is Vor Biopharma's operating income?
Vor Biopharma's total operating income in 2025 was -$371.64 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $371.64 million
How has Vor Biopharma's revenue changed over the last 5 years?

Over the last 5 years, Vor Biopharma's total revenue changed from $0.00 in 2020 to $0.00 in 2025, a change of 0.0%.

How much debt does Vor Biopharma have?

Vor Biopharma's total liabilities were at $628.44 million at the end of 2025, a 1,259.5% increase from 2024, and a 2,173.9% increase since 2020.

How much cash does Vor Biopharma have?

In the past 5 years, Vor Biopharma's cash and equivalents has ranged from $31.36 million in 2023 to $396.49 million in 2025, and is currently $396.49 million as of their latest financial filing in 2025.

How has Vor Biopharma's book value per share changed over the last 5 years?

Over the last 5 years, Vor Biopharma's book value per share changed from -276.45 in 2020 to -15.78 in 2025, a change of -94.3%.


Related Companies

Financial statements for NASDAQ:VOR last updated on 4/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon’s AI supercomputer just went live. Here’s my #1 stock.
Is Elon about to trigger another 315X opportunity? Elon gave Tesla investors the chance to make more than 3...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel